Sosei Group Corporation
E474941
Sosei Group Corporation is a Japan-based biopharmaceutical company that develops and acquires innovative drug discovery technologies and therapeutics through subsidiaries such as Heptares Therapeutics.
All labels observed (1)
| Label | Occurrences |
|---|---|
| Sosei Group Corporation canonical | 2 |
How this entity was disambiguated
This entity first appeared as the object of triple T4850473 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: Sosei Group Corporation Context triple: [Heptares Therapeutics, parentOrganization, Sosei Group Corporation]
-
A.
Keihan Group
Keihan Group is a Japanese corporate conglomerate centered on the Keihan Electric Railway that operates transportation, real estate, retail, and leisure businesses in the Kansai region.
-
B.
Taisei Corporation
Taisei Corporation is a major Japanese construction and civil engineering company known for leading large-scale infrastructure and landmark building projects in Japan and abroad.
-
C.
Obayashi Corporation
Obayashi Corporation is a major Japanese construction and engineering company known for its involvement in large-scale infrastructure and building projects worldwide.
-
D.
Takenaka Corporation
Takenaka Corporation is a major Japanese architecture, engineering, and construction firm known for designing and building prominent structures domestically and internationally.
-
E.
Marui Group
Marui Group is a Japanese retail and financial services company best known for operating fashion-oriented department stores and providing credit card and related consumer finance services.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: Sosei Group Corporation Target entity description: Sosei Group Corporation is a Japan-based biopharmaceutical company that develops and acquires innovative drug discovery technologies and therapeutics through subsidiaries such as Heptares Therapeutics.
-
A.
Keihan Group
Keihan Group is a Japanese corporate conglomerate centered on the Keihan Electric Railway that operates transportation, real estate, retail, and leisure businesses in the Kansai region.
-
B.
Taisei Corporation
Taisei Corporation is a major Japanese construction and civil engineering company known for leading large-scale infrastructure and landmark building projects in Japan and abroad.
-
C.
Obayashi Corporation
Obayashi Corporation is a major Japanese construction and engineering company known for its involvement in large-scale infrastructure and building projects worldwide.
-
D.
Takenaka Corporation
Takenaka Corporation is a major Japanese architecture, engineering, and construction firm known for designing and building prominent structures domestically and internationally.
-
E.
Marui Group
Marui Group is a Japanese retail and financial services company best known for operating fashion-oriented department stores and providing credit card and related consumer finance services.
- F. None of above. chosen
Statements (46)
| Predicate | Object |
|---|---|
| instanceOf |
biopharmaceutical company
ⓘ
public company ⓘ |
| acquired | Heptares Therapeutics ⓘ |
| businessModel |
drug discovery and development
ⓘ
technology licensing ⓘ |
| collaboratesWith |
academic research institutions
ⓘ
biotechnology companies ⓘ major global pharmaceutical companies ⓘ |
| coreBusiness |
development of biologics
ⓘ
discovery of novel small-molecule drugs ⓘ |
| country | Japan ⓘ |
| engagesIn |
early-stage clinical development
ⓘ
preclinical research ⓘ |
| focusesOn |
innovative drug discovery technologies
ⓘ
targeted therapies ⓘ therapeutics development ⓘ |
| foundedIn | Japan ⓘ |
| hasAlternativeName |
Sosei Heptares Group
ⓘ
linked to:
Sosei Heptares
|
| hasKeyTechnology |
GPCR-targeted drug discovery platform
ⓘ
structure-based drug design platform ⓘ |
| hasOffice |
Cambridge, United Kingdom
ⓘ
linked to:
Cambridge, England
|
| hasResearchArea |
central nervous system disorders
ⓘ
gastrointestinal diseases ⓘ immunology ⓘ inflammatory diseases ⓘ metabolic diseases ⓘ |
| hasSubsidiary |
Heptares Therapeutics
ⓘ
Sosei Heptares ⓘ |
| headquartersLocation | Tokyo ⓘ |
| industry |
biotechnology
ⓘ
pharmaceuticals ⓘ |
| languageOfName | Japanese ⓘ |
| listedOn | Tokyo Stock Exchange ⓘ |
| operatesIn |
Japan
ⓘ
United Kingdom ⓘ |
| regionServed | global ⓘ |
| regulatoryEnvironment |
Japanese pharmaceutical regulation
ⓘ
international pharmaceutical regulation ⓘ |
| sector | healthcare ⓘ |
| specializesIn | G protein-coupled receptor (GPCR) drug discovery ⓘ |
| strategy |
acquisition of innovative drug discovery technologies
ⓘ
partnering for clinical development and commercialization ⓘ |
| tickerSymbol | 4565 ⓘ |
| typeOfOwnership | publicly traded ⓘ |
| usesTechnology |
stabilized GPCR technology
ⓘ
structure-based drug design ⓘ |
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
Instruction
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Input
Subject: Sosei Group Corporation Description of subject: Sosei Group Corporation is a Japan-based biopharmaceutical company that develops and acquires innovative drug discovery technologies and therapeutics through subsidiaries such as Heptares Therapeutics.
Referenced by (2)
Full triples — surface form annotated when it differs from this entity's canonical label.